O'Dwyer PJ - Search Results

1

Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.

Perez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC. Perez RP, et al. Int J Cancer. 1991 May 10;48(2):265-9. doi: 10.1002/ijc.2910480219. Int J Cancer. 1991. PMID: 2019469

2

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, Ozols RF. Bookman MA, et al. J Clin Oncol. 1996 Jun;14(6):1895-902. doi: 10.1200/JCO.1996.14.6.1895. J Clin Oncol. 1996. PMID: 8656258 Clinical Trial.

3

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. Godwin AK, et al. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070-4. doi: 10.1073/pnas.89.7.3070. Proc Natl Acad Sci U S A. 1992. PMID: 1348364 Free PMC article.

4

The role of glutathione in drug resistance.

Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC. Ozols RF, et al. Cancer Treat Rev. 1990 Dec;17 Suppl A:45-50. doi: 10.1016/0305-7372(90)90015-8. Cancer Treat Rev. 1990. PMID: 2092870 Review. No abstract available.

5

Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.

Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ, Hamilton TC. Yao KS, et al. Cancer Res. 1995 Oct 1;55(19):4367-74. Cancer Res. 1995. PMID: 7671249

6

Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells.

Perez RP, Johnson SW, Handel LM, O'Dwyer PJ, Hamilton TC. Perez RP, et al. Gynecol Oncol. 1995 Sep;58(3):312-8. doi: 10.1006/gyno.1995.1236. Gynecol Oncol. 1995. PMID: 7672697

7

Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.

Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ. Yao K, et al. Cancer Res. 1993 Aug 15;53(16):3662-6. Cancer Res. 1993. PMID: 8101766 Clinical Trial.

8

Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.

Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Hamaguchi K, et al. Cancer Res. 1993 Nov 1;53(21):5225-32. Cancer Res. 1993. PMID: 8106143

9

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ. Haas NB, et al. Cancer Res. 1994 Mar 1;54(5):1220-6. Cancer Res. 1994. PMID: 8118810 Clinical Trial.

10

Clinical reversal of drug resistance in ovarian cancer.

Ozols RF, O'Dwyer PJ, Hamilton TC. Ozols RF, et al. Gynecol Oncol. 1993 Oct;51(1):90-6. doi: 10.1006/gyno.1993.1252. Gynecol Oncol. 1993. PMID: 8244181 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

548 results

Search Page

Filters